Clinical trial Recruiting at 1 site Observational Ages 18 and up

Comparing inflammation markers from dried blood spots and standard blood draws

Official title: Analysis of Inflammatory Biomarker Changes in Dry Blood Spot Versus Venous Blood Samples

Run by McGill University Health Centre/Research Institute of the McGill University Health Centre · NCT07435285 · Data updated 2026-11-12

This will see if finger‑prick dried blood spot samples can measure inflammation markers as accurately as standard venous blood draws in adults receiving a planned vaccine or other scheduled stressor.

More Inflammation Biomarkers trials

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment50 (estimated)
SponsorMcGill University Health Centre/Research Institute of the McGill University Health Centre
Academic / other
Locations1 site (Montreal, Quebec)
StatusRecruiting
StartedJanuary 15, 2026
Main results expectedDecember 2026
Study endsDecember 2026
Registry record updatedMarch 27, 2026
Trial IDNCT07435285 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18 and older who are planning to receive a seasonal vaccine or have another scheduled acute stressor and who do not have recent infectious symptoms or recent acute worsening of chronic disease.

Probably not a fit

People with recent infection symptoms, recent use of certain recreational drugs, recent acute worsening of chronic conditions, a contraindication to the planned vaccine, or those not undergoing a planned stressor are unlikely to benefit from participating.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults planning to receive a seasonal vaccine or another planned acute stressor provide paired dried blood spot (DBS) and venous blood samples before and after the event to capture changes in inflammatory biomarkers. Investigators measure and compare concentrations and changes in biomarkers in DBS versus matched venous samples to determine agreement and reliability. The protocol excludes people with recent infectious symptoms, recent substance use, or recent acute worsening of chronic disease to avoid confounding inflammation signals. Results will inform whether DBS can serve as a practical alternative to clinic-based venous sampling for future research and decentralized monitoring.

Why it matters

Potential benefit: If successful, DBS sampling could allow easier at‑home or remote collection for monitoring inflammation, reducing the need for clinic visits and venous draws.

How similar studies have gone: Previous work has shown DBS can reliably measure some inflammation markers such as CRP, but results are variable for certain cytokines, so DBS is promising but not yet universally validated for all inflammatory biomarkers.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Men or women aged ≥18 years, who are planning to receive a seasonal vaccine OR have a scheduled acute stressor\*.

Exclusion Criteria:

* Any infectious symptoms (fever, cough, rhinorrhea, sore throat, diarrhea, loss of smell or taste) within the previous 7 days
* Any self-reported active/recent use of cocaine, injection drugs, or amphetamines
* Acute worsening of a known chronic health condition within the previous 30 days (e.g., of IBD, COPD, asthma, rheumatologic disease)
* Known severe allergy or intolerance to the planned vaccine
* Contraindication to the vaccine received, if applicable

  \*List of possible scheduled acute stressors include:
* Hard exercise (incl. 10km run or longer, high-intensity interval training, or comparable endurance activity)
* Social event with moderate alcohol consumption
* Planned change in medication dose and/or frequency of use
* Onset of menstruation (day 1)
* Other pre-planned stressors expected to elicit an inflammatory response

Where it's running

  • Research Institute of the McGill University Health Centre
    Montreal, Quebec, Canada
    Recruiting

Study contacts

  • Principal investigator: Emily G. McDonald, MD MSc — McGill University Health Centre/Research Institute of the McGill University Health Centre
  • Study coordinator: Kristen Moran, BSc.
  • Email: cpau.med@mcgill.ca
  • Phone: 514-934-1934

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.